This study highlights RNA therapeutics’ transformative potential, bridging gene-level precision with clinical reality to redefine future personalized medicine.

Combining biomaterial scaffolds with nucleic acid vectors enhances safety, delivery efficiency, and controlled release for regenerative medicine applications.

Dose-optimized iron oxide nanoparticles may reinforce tomato's antioxidant defenses, offering a promising, low-input route to drought resilience.

This review consolidates biosensor performance evidence, demonstrating their rising diagnostic reliability and strengthening their adoption across diverse clinical and point-of-care settings.

Electrochemical heavy-metal sensors achieve trace-level sensitivity, but fouling, organic-matter binding and unvalidated algorithms still block dependable long-term field water monitoring.

Organoid-based screening exposes nano–bio behaviour that two-dimensional culture hides, making theranostic nanomedicine selection patient-specific, heterogeneity-aware and clinically translatable.

Microfluidic continuous-flow manufacturing can turn theranostic liposomes from bespoke laboratory preparations into reproducible, scalable, GMP-ready products fit for clinical trials.

Corona engineering converts nanocarrier surface chemistry into a controllable determinant of circulation time, hepatic escape and tumour delivery.

Glucose-responsive nanogels can autonomously sense hyperglycemia and release insulin proportionally, offering a needle-sparing route toward hypoglycemia-free, self-regulated diabetes care.

Treating light as a programmable reagent lets chemists sculpt nanocrystal shape, size and handedness with spatial, spectral and temporal precision.

This review explains why most nanomedicines fail clinically and outlines integrated biological, manufacturing and regulatory strategies to accelerate patient access.

Integrating diagnostic, therapeutic and regenerative nanotechnologies clarifies which platforms are clinically ready and which translational barriers demand coordinated, standardised research.

Integrating clinical, toxicological, ethical, and regulatory evidence, this review shows nanomedicine's benefits depend on safety-by-design, harmonised regulation, and equitable access.

Smart nanomaterials unite sensing, targeted therapy and AI-guided monitoring, but standardized safety testing and scalable manufacture must precede clinical adoption.

Patient-derived organoids expose subclone-specific nanoparticle delivery that conventional models conceal, redirecting theranostic design toward the cells driving colorectal cancer relapse.